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Structural Modifications of Proteins During Aging 
Ari Gafni, PhD 
ging is a fundamental phenomenon that affects somatic A cells whose manifestations, however, may differ from 
one cell type to another. While most of us possess an intuitive 
understanding of what aging is, and can tell a young person 
from an old one, a precise definition of aging and its relation- 
ship to development has been surprisingly difficult to develop. 
The phenomenon of senescence can be defined descriptively 
as the highly complex ensemble of deteriorative processes 
that slowly, and irreversibly, increase the susceptibility of an 
organism to disease and predispose it to death. By emphasiz- 
ing those processes that lead to a decline in the ability of the 
organism to cope with environmental stresses, this definition 
allows one to intuitively, though somewhat arbitrarily, sepa- 
rate aging from development (the latter process installing, 
and enhancing, an organism’s ability to adapt to its environ- 
ment and to respond to changes in it). The drawback of this 
very general definition of aging, however, is that it gives no 
clue as to the fundamental biological processes that regulate, 
or are involved in, the aging process and provides no indica- 
tion of the mechanisms by which these processes manifest 
themselves. 
A number of hypotheses to explain the origin of biolog- 
ical aging and to provide more mechanistic insight have been 
developed and are able to be tested by experiment. These 
have been described in a number of recent reviews and 
research  publication^.'-^ The aim of the present review is to 
provide a somewhat more focused description of one aspect 
of aging, the age-related changes in proteins, thus summariz- 
ing the current knowledge of the aging phenomenon at its 
most elementary level, the molecular level . 
Proteins are macromolecules that serve to execute, regu- 
late, and mediate nearly all biological functions in the cell as 
well as in the intercellular matrix. The complexity of life 
processes requires that hundreds, even thousands, of different 
proteins be present in a living cell at  any given moment, each 
performing a specific task (a typical example being the catal- 
ysis of a single chemical reaction within a sequence of reac- 
tions that together carry ou t  a biological process). To ensure 
that only reactions beneficial to the organism occur to any 
significant extent, proteins need not only be very efficient and 
specific in their function but must also possess the ability to 
be regulated by external stimuli (for example by becoming 
phosphorylated in response to signals from hormones, etc.) 
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so that their activities can be turned on or off upon demand. 
To achieve these diverse properties, proteins have evolved to 
be extremely modular macromolecules. They are comprised 
of linear chains of covalently linked combinations of the 20 
natural amino acids (a typical polypeptide chain being a few 
hundred residues long). Each protein has a specific, unique, 
sequence that determines its identity and biological nature. 
This sequence is assembled on the ribosome by translating the 
message contained in the sequence of nucleotides of the 
messenger RNA encoding the protein which, in turn, has 
been transcribed from the message encoded by the sequence 
of the DNA that comprises the gene specific for that protein.’ 
The one-to-one correspondence between the sequence of 
nucleotides in a gene and the sequence of amino acids in the 
protein encoded by that gene is commonly referred to as the 
genetic code. 
The successful synthesis of a polypeptide chain is, how- 
ever, not sufficient to generate biological activity. To become 
a functional protein the nascent polypeptide chain that comes 
off the ribosome has to fold into a very precise, compact, 
three-dimensional structure. Failure to do so yields a defec- 
tive, usually nonfunctional, protein. It is generally believed, 
based on a variety of experimental results and theoretical 
arguments, that all the information needed to produce the 
native structure of a protein is contained in the sequence of 
amino acids in its polypeptide chain.’v9 The self organizing 
process, in which this one-dimensional message is translated 
into a three- dimensional structure, is termed protein fold- 
ingl0-l2 and is frequently referred to as the second half of the 
genetic code. A basic strategy of folding is believed to be the 
production of partially folded intermediates that contain 
local structural motifs (secondary structure) and which, being 
flexible and relatively unstable, continue to “fine-tune” their 
structure to achieve the more stable native state. This process 
is schematically depicted in Figure 1. It is pertinent to note, 
however, that although protein folding has been studied for 
more than 30 years, it is still not fully understood, and this 
process continues to pose one of the major unresolved prob- 
lems of contemporary biology. Moreover, we now know that 
most proteins in the cell are assisted in their folding by a 
special class of helper proteins, the molecular chaperones, 
whose role in directing the folding to produce the biologically 
functional structure (possibly by inhibiting competing path- 
ways that lead to misfolded, inactive, species) is currently 
being pursued vigorously.’”-’s 
Because the sequence of amino acids determines the 
ultimate structure, and, hence, the functional competence of 
a protein, it is not surprising that even small changes in this 
sequence sometime have profound effects on the biological 
activity. When the substituted amino acid is one that is 
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Figure 1. A schematic depiction of the unassisted folding of a 
protein in vitro. The process begins when the unfolded polypep- 
tide chain, which is devoid of ordered three-dimensional struc- 
ture and of biological function, rapidly collapses to generate a 
compact, but flexible, “molten globule” intermediate where 
elements of secondary structure (alpha helices and beta-sheet 
domains) have already formed but have not yet interacted to 
create the tertiary, native structure of the protein. The latter 
precisely folded and more rigid structure subsequently evolves 
through a “fine-tuning” process. In the cell protein folding is 
assisted by a special class of proteins, the molecular chaperones. 
However, both in vitro and in vivo the folded structure is 
believed to be determined uniquely by the sequence of amino 
acids in the polypeptide chain, and since it is usually only 
marginally stable, even slight changes in this sequence will usu- 
ally produce a distinctly different structure. 
essential for the biological function of the protein, such effects 
are obvious; however, what is less commonly appreciated is 
that in many cases, mutations replace residues that are not 
involved directly in the biological function but that are rather 
crucial for competent folding or for the stabilization of the 
folded state. Indeed, the failure of mutant proteins to fold 
correctly is one of the major causes for their abnormal behav- 
ior associated with genetic  disease^.'^-'^ It is pertinent to 
note, however, that structural changes may also develop in 
protein molecules that have initially folded correctly, leading 
to a loss or a modification in their biological activities. A 
number of processes can yield such behavior, including the 
introduction of covalent modifications (oxidation, glycation, 
deamidation, methylation, etc.), the isomerization of specific 
amino acid residues within the protein (cis-trans isomeriza- 
tion of proline residues, racemization of aspartyl residues), or 
a change in the structure of the folded state of the protein. 
Examples of such alterations can be found in proteins iso- 
lated from old organisms and will be presented in the discus- 
sion that follows. 
The presence of modifications in proteins isolated from 
tissues of old animals relative to those isolated from young 
controls has been well documented, and this topic has been 
covered in several  review^.^'-^' These modifications have 
been found to involve the functional properties, the stability, 
as well as the structural integrity of these proteins. Old 
proteins (i,e., those found in tissues of old animals) often, 
though not always, display a reduction in their biological 
activity,26-28 a mpdified heat inactivation pattern reflecting 
alterations in their ~ t a b i l i t y , ~ ~ - ~ ’  and frequently possess a 
modified affinity to antibodies raised against the young form 
of the protein, a reflection of changes in structural integri- 
ty.32,33 The fact that, as a rule, those proteins whose activity 
is affected by aging, display reduced (rather than enhanced) 
biological competence is not surprising as evolution has 
strongly selected for each protein a structure that possesses a 
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high biological activity, and a change in the former is likely to 
reduce the latter. Because most intracellular proteins turn 
over rather quickly (within hours to days), there is less 
evolutionary pressure for high stability, and changes in this 
parameter with aging are less unidirectional. Indeed, it is well 
documented that proteins isolated from old tissues can dis- 
play either increased or decreased stabilities; examples of 
these two behaviors are given in Figure 2. 
The changes observed in the biological activity associ- 
ated with a given protein in the cell may, in principle, be 
caused by a decline in the efficiency of protein synthesis (i.e., 
a smaller quantity of protein being made), by alterations in 
the fidelity of the synthesis of the protein (i.e., errors in the 
amino acid sequence), or by posttranslational modifications 
in the protein (attributable either to chemical alterations or to 
changes in the folding). A decline in protein synthesis with 
aging, while potentially of great general importance, does not 
involve changes in structure and is, therefore, outside the 
scope of the current review. The appearance with aging of 
alterations in the fidelity of protein synthesis have, in the past, 
received much attention, as such alterations were the basis for 
Orgel’s Error Catastrophe theory.3435 This theory was based 
on the assumption that the low level of errors introduced into 
protein sequences during normal synthesis will tend to in- 
crease exponentially with advancing age because some of the 
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Figure 2. The effects of aging on the heat stability of two proteins 
isolated from rat muscles. The upper box presents the kinetics of 
inactivation of glyceraldehyde-3-phosphate dehydrogenase sam- 
ples isolated from young (Y) and old (0) rats upon incubation at 
46” C. The old enzyme is clearly more heat labile. The lower box 
presents similar data obtained for phosphoglycerate kinase incu- 
bated at 44” C revealing, in contrast, a dramatic increase in the 
heat stability of the old form of this enzyme. 
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erroneous proteins initially randomly created will be enzymes 
involved in protein synthesis. Defects in these proteins will 
result in an increased level of ill-produced new proteins, and 
this vicious cycle, where the errors are amplified in each 
consecutive generation of protein, would lead to catastrophic 
conditions for the cell. Orgel’s theory stimulated a burst of 
experimental work searching for modified proteins in aging 
cells and, while many were discovered, no evidence for error 
amplification was found. More specifically, all the evidence 
gathered thus far points to postsynthetic modifications as the 
origin of protein aging, in stark contrast to the main tenet of 
the Error Catastrophe hypothesis. These postsynthetic alter- 
ations are the topic for the discussion below. 
CLASSIFICATION OF AGING-RELATED PROTEIN 
MODIFICATIONS 
Broadly defined, the observed aging-related modifica- 
tions in proteins fall into two categories: covalent and con- 
formational. Both types of modifications lead to structural 
changes and, as a rule, to alterations in the biological activity 
of a protein; however, there is an important distinction be- 
tween them. Conformational information is erased when the 
protein is unfolded, and modifications of this type may, 
therefore, be removed by subjecting the old protein to an 
unfolding-refolding protocol as will be described below. Co- 
valent modifications, in contrast, are more permanent be- 
cause they change the identity of the affected amino acids, 
and this modified sequence, as a rule, will refold into the 
altered structure. Both covalent and conformational alter- 
ations tend to predispose a protein to proteolysis, and it is the 
decline in the latter process with aging that may be a major 
reason for the observed increase in the level of modified 
proteins. It is also of interest to mention that since these 
age-related modifications are post synthetic, they may all be 
expected to be more prevalent in long lived proteins relative 
to those with short dwell times in the tissue. 
In the discussion that follows, several specific mecha- 
nisms that introduce aging-related covalent modifications in 
proteins will be described. These have been found to alter 
both the structural and functional properties of the protein 
involved. The most prevalent covalent modifications are in- 
troduced by oxidation, glycation, or by deamidation and its 
related reactions. This section will be followed by a discus- 
sion of the origin of conformational differences between the 
young and old forms of a protein, which can reflect either a 
failure to fold correctly because of modified conditions in the 
old cell or the development of conformational transitions 
subsequent to an initially correct folding. 
Oxidation 
Oxidative free radicals are produced constantly in the 
cell as byproducts of normal metabolic processes. These 
highly reactive species can rapidly interact with, and damage, 
various cellular components (proteins, nucleic acids, lipids). 
Indeed, it has been estimated that between 10,000 and 
100,000 DNA bases are modified by oxygen free radicals in 
an average cell every day.36 Although cells have defense 
mechanisms against free radical attack, including those pro- 
vided by chaperone-proteins as cu-cry~tallin,~’ this protection 
is not perfect, and a low level of oxidation occurs continu- 
ously. Moreover, there is evidence that the efficiency of pro- 
tection against free radical attack may decline with advancing 
age, leading to an increased rate of damage accumulation. 
Indeed, inasmuch as some of the enzymes involved in oxida- 
tive damage control may themselves be affected by free radi- 
cal oxidation, one would expect the rate of such damaging 
reactions in the cell to increase with age in an ever- 
accelerating process conceptually akin to the one postulated 
by the Error Catastrophe theory. Evidence for this type of 
behavior has been found, and will be discussed below. 
The potential role of oxidative free radicals in both aging 
and disease has been recognized for many years. As early as 
1956, Harman proposed his now famous “free radical theory 
of aging.”38~3’ Although a large number of studies have 
addressed this issue since our understanding of the 
role of oxidative stress in aging is still incomplete, and the 
question of whether oxidation of cellular components is a 
causative factor in aging or a result of this process brought 
about by a decline in cellular defense mechanisms has not 
been fully answered. It is clear, however, that some proteins 
in old organisms are modified substantially by oxidation. 
Support for this statement is provided both by the observa- 
tion that proteins from old animals contain covalent modifi- 
cations that are clearly the result of oxidation reactions and 
by the ability to mimic the age-related modifications in pro- 
teins by their exposure to oxidative conditions in 
From the functional point of view, the two characteristics of 
a protein that are most noticeably affected by oxidation are 
the biological activity and the heat stability. The former, 
when affected, invariably decreases whereas the latter can 
change in complex ways and sometimes increases. The ap- 
pearance of modifications involving oxidation in a protein 
marks this protein for degradation by a number of cellular 
p r ~ t e i n a s e s . ~ ~ . ~ ’  The accumulation of oxidized proteins dur- 
ing aging is believed to be the result not only of the acceler- 
ated rate of oxidation but, as importantly, of the age-related 
decline in the efficacy of these proteinases.sO*”’ 
One of the prominent age-related oxidative modifica- 
tions in proteins is the increase in carbonyl content, a product 
of the oxidation of several amino acid side chains, including 
proline, arginine, and lysine, as well as of oxidation reactions 
that lead to the cleavage of peptide bonds.-52 A schematic 
depiction of carbonyl formation by this reaction is given in 
Figure 3. Indeed, several researchers have demonstrated that 
NH 
K1+-o NH 
0 (OH xidizing ’, HOC) K j S o  + It3< 0 
Free Radicals 
NII, 
K3 q0 
NH 
Figure 3. One of the common results of the oxidation of a protein 
by reactive free radicals is the cleavage of the polypeptide chain, 
which is accompanied by the introduction of new carbonyl 
groups. 
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the carbonyl content of proteins in a large number of different 
tissues, as well as in whole body homogenates, increases 
exponentially with It has been estimated that about 
30 to 50% of total cellular proteins in an old animal may be 
a range typical of the reduction in the catalytic 
activity observed for many enzymes in old organisms. It is 
important to note here that carbonyl groups are also intro- 
duced into proteins (though transiently) during glycation 
(discussed in the next section) where a long-lived intermedi- 
ate, the Amadori product, contains this group (see Fig. 4). 
Protein glycation thus adds to the pool of carbonyl- 
containing proteins in a way that is affected by disease (dia- 
betes) and, probably, by aging. 
Although the carbonyl content of proteins can be deter- 
mined experimentally5' and has, therefore, been documented 
and studied in some detail, it is pertinent to mention that the 
oxidation of some amino acid residues does not lead to the 
production of these functional groups. Carbonyls are, there- 
fore, not the only result of free radical-mediated protein 
damage that occurs in aging. For example, histidine oxida- 
tion produces aspartate or asparagine, proline oxidation 
produces glutamate, and cysteine oxidation yields disulfide 
bonds; in none of these cases are carbonyls generated.J6 
Oxidation of the aromatic amino acid residues phenylala- 
nine, tyrosine, and tryptophan can produce their respective 
hydroxy derivatives, again generating no carbonyls. It is, 
clear, therefore, that the carbonyl content of a protein does 
not reflect the full extent of potential oxidative damage. 
As mentioned previously, the oxidation of proteins often 
leads to discernible changes in their biological and physical 
properties, including changes in stability, in the ability to be 
recognized by proteolytic enzymes, and in some spectro- 
scopic signatures. Although oxidation may alter only a very 
limited number of amino acid residues in a protein directly, 
sometimes only one, the observed effects may reflect struc- 
tural alterations that encompass more global protein struc- 
ture. Thus, it should be appreciated that often it is the 
oxidation of residues that are not a part of the active site of an 
enzyme and that do not, therefore, participate in catalysis, 
that brings about the observed oxidation-related effects. In 
this respect the alteration of an amino acid residue by oxida- 
tion resembles the effect of a point mutation in that it modifies 
the code for the folded state of the protein. The difference is 
that the modification in this code caused by a mutation in the 
gene is incorporated into the nascent polypeptide and, hence, 
affects the proteins' folding process, whereas oxidation (say 
of a proline to glutamate) occurs subsequent to the original 
folding, and its structural consequence is caused by the pro- 
teins' readjustment to the introduction of a new group into its 
prefolded structure. Whether this new structure is identical to 
the one that would have been generated by folding of the 
premodified polypeptide chain is an interesting question that 
has not been carefully studied. It would also be of interest to 
characterize the structural modifications introduced into pro- 
teins in response to amino acid oxidation by comparing the 
X-ray-derived structures of the original and the oxidized 
protein forms. This, also, has not been attempted yet. 
Protein Glycution 
Glycation, or nonenzymatic glycosylation, of proteins is 
a complex reaction, depicted schematically in Figure 4. The 
reaction begins when a carbonyl group of a sugar (frequently 
glucose) reacts with an amino group on a protein (usually a 
H 84-4' CHa-NH-P 
moatha Carboxymthyly~lns 
"\,P 'C' 
hours 1 days 
.Id 
I 
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I Pentosldlnr I 
Glucose Schln Amadorl 
Brse Product 
AGE 
Prod& 
Figure 4. The protein glycation reaction. The carbonyl group of 
a sugar (here glucose) reacts with a free amino group on the 
protein to form a Schiff base. This relatively rapid and reversible 
reaction is followed by the slower, but still reversible, Amadori 
rearrangement. The free carbonyl group of the Amadori product 
subsequently undergoes a series of interactions that lead to the 
slow and irreversible production of the advanced glycosylation 
end products, including cross-linked protein species. 
lysine or the N-terminal amino group) to form a Schiff base. 
This derivative reacts further, by an Amadori rearrangement, 
to produce a ketoamine, which is subsequently crosslinked 
and converted by a complex pathway to advanced glycosyla- 
tion end products ( AGE-products), which are fluorescent, 
brown  pigment^.'^''^ Although not displayed explicitly in 
Figure 4, oxidation by molecular oxygen plays an important 
role in glycation in two major ways: (1) it is involved in some 
of the steps leading to the formation of the AGE-prod- 
U C ~ S , ~ ~ ' ~ '  and (2) oxidation of the participating sugar can 
produce reactive dicarbonyls (such as glyoxal) that interact 
rapidly with amino groups on the protein to ultimately pro- 
duce N-carboxymethyl amino-acid derivatives (most fre- 
quently from lysine). The term autoxidative glycosylation has 
been coined to describe these reactions.61 
The time scales involved in these protein modifications 
have been studied both in vitro and in vivo, and whereas the 
formation of the Schiff base can occur within a few hours 
under conditions like those found in the cell, the Amadori 
product typically takes several days to form, and the AGE- 
products develop relatively slowly over a period of weeks to 
months.62 Unlike the Schiff base and the Amadori product, 
however, both of which are formed by reversible reactions 
and are thus present at  steady state levels, the AGE-products 
contain irreversible modifications and tend to accumulate 
over time. If the target protein is one that has a long dwell 
time in the cell, the extent of glycation may become very 
significant. Because the degree of glycation increases over 
time, it is not surprising that its products are enhanced 
significantly with aging (and even more so in diabetic subjects 
whose glucose levels are elevated, thereby speeding up the 
process). 
Extracellular matrix proteins tend to be longer-lived 
than their intracellular counterparts, and are, therefore, gen- 
erally more markedly altered by glycation. Indeed, in almost 
all species studied so far, an aging-related increase in the level 
of glycated extracellular proteins has been observed. One of 
the best studied cases is collagen, where a build up with age of 
glycated lysines has been documented in a number of stud- 
ies.63-66 The crosslinking of collagen type I by glycation was 
shown to induce an expansion of the molecular packing6' 
and to covalently cross-link this protein to soluble plasma 
pr0teins,6*-~' possibly contributing to the narrowing of the 
vascular lumen. In basement membrane collagen, as well as in 
laminin, the AGE-products were found to interfere with 
normal associations and with self assembly of these pro- 
t e i n ~ . ~ ~ ' ~ '  Glycation-induced abnormalities in the extracellu- 
lar matrix were found to alter both the structure and the 
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function of intact vessels and have been implicated as a 
contributing factor in a therosc le r~s is .~~  An age-related in- 
crease in the level of glycation of the very long lived eye-lens 
crystallin has been reported to occur in bovine lenses74 but, 
surprisingly, not in human or rat Thus, the reac- 
tion may be species-dependent. It is important to mention 
that some intracellular proteins, whose turnover rate is slow, 
are also susceptible to AGE-product formation. Thus, red 
blood cell hemoglobin, whose dwell-time in human erythro- 
cytes is ca 120 days, is glycosylated measurably, and the 
extent of modification increases significantly in diabetes.77 It 
is interesting to note that the small heat-shock protein, alpha 
crystallin, has recently been shown to effectively protect a 
number of proteins against glycation in ~ i t r o . ~ * - ~ "  Whether 
this protein affords a similar protection to cellular proteins in 
vivo remains to be tested. 
Although the relatively high turnover rate of most intra- 
cellular proteins makes them less likely to form AGE- 
products, these proteins can react with sugars to produce 
significant amounts of the more rapidly forming Amadori 
product. Such a modification was found to occur in liver 
alcohol dehydrogenase in vivo." Several recent reports reveal 
that the glycolytic enzyme glyceraldehyde-3-phosphate dehy- 
drogen-se (GAPDH) isolated from rabbit muscle or from 
erythrocytes is also partially gly~ated. '~ , '~  While the chemi- 
cal identity of the glycation product was not determined, it 
was found to be quite stable as glycated GAPDH could be 
isolated and studied. This may indicate that glycation went 
beyond the Amadori product. The activity of glycated 
GAPDH was found to be reduced relative to that of the native 
enzyme, and modifications to its tertiary (but not the second- 
ary) structure were found that were assigned to the active site 
domaimx2 
Deamidation, Racemization, and Isomerization 
The three postsynthetic, protein-modifying reactions in 
this class all involve asparagine residues. In deamidation, an 
asparagine is hydrolyzed to produce aspartate and ammonia. 
Since aspartate is ionized at physiologic pH, this reaction 
introduces one negative charge into a protein for each deami- 
dation event. In a series of studies, Gracy and coworkers have 
demonstrated that deamidation increases with aging in a 
number of proteins and that in both triose-3-phosphate 
isomerase and glucose-6-phosphate isomerase the electro- 
static repulsion among the negative charges produced desta- 
bilizes the enzymes and make them more susceptible to pro- 
teoIy~is .*~- '~  
Two by-products of the deamidation of asparagine resi- 
dues in proteins are isoaspartate and D-aspartate. In the 
production of isoaspartate, shown in Figure 5, the side-chain 
carboxyl group becomes connected in the peptide bond, 
freeing the alpha carboxyl. The generation of D-aspartate is 
caused by a racemization (the conversion of the native L- 
amino acid into its optical antipode). A detailed mechanism 
for asparagine deamidation, isomerization, and racemization 
was developed by Clarke and  coworker^,^^^^^ who demon- 
strated that in a protein the rates of these reactions depend 
both on the amino acid that follows the asparagine residue in 
the sequence and on the three-dimensional structure of the 
protein, the latter imposing conformational restrictions on 
these reactions. It is pertinent to mention that, as a rule, 
racemization of amino acids is a slow process under physio- 
logic conditions and that aspartic acid, which is the most 
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Figure 5. The deamidation of an asparaginyl residue in a protein 
proceeds in two steps. First, a succinimide intermediate is pro- 
duced from asparagine in a reaction that is driven by the release 
of ammonia. The succinimide then undergoes hydrolysis by 
water, a reaction that can yield either an aspartyl or an isoaspar- 
ty l  product. In both cases, a new negative charge is generated on 
the protein; however, the production of isoaspartyl also intro- 
duces a non-native linkage into the polypeptide chain. 
susceptible to this reaction of all the natural amino acids, only 
undergoes the transition at  a rate of about 0.14% per year. It 
is, therefore, to be expected that even in old tissues only a 
relatively small fraction of Asp residues are modified. Indeed, 
the accumulation of modified aspartate is only significant in 
long-lived proteins and has been documented in the eye lens, 
where protein turnover is almost nonexistent, and in red 
blood cells where the dwell-time of proteins is several 
 month^.'^-^^ Thus, while isomerization and racemization of 
asparagine can lead to protein modification, their contribu- 
tion to the pool of altered proteins is relatively small and will 
not, as a rule, alter most cellular proteins, whose turnover 
rate is too high to be affected. 
CONFORMATIONAL ALTERATIONS AND 
AGGREGATION 
Age-Related Conformational Alterations 
Because the biological activity of a protein depends crit- 
ically on the precise three-dimensional structure of its folded 
state, it is not difficult to envision that any alteration in this 
structure may have profound effects on the proteins' biolog- 
ical activity. The hypothesis that many of the age-related 
declines in functional properties of proteins are attributable 
to conformational modifications was first put forward by 
R~thstein,~-~-"  who suggested that this behavior may be 
caused by the longer dwell-time of proteins in the cells of old 
animals. Strong, though not conclusive, evidence in support 
of conformational changes as the origin of the age-related 
modification in a number of proteins was subsequently pro- 
vided. Thus, Sharma and R o t h ~ t e i n ~ ~  demonstrated that the 
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young and old forms of the glycolytic enzyme enolase (isolat- 
ed from young and old nematodes, respectively), which dis- 
play different activities, share the same amino acids sequence; 
however, when these two enzyme species were unfolded by 
guanidine:HCl (a strong denaturant of proteins) and then 
allowed to refold, they formed an identical structure similar 
to that of old enolase. Strong evidence was also found for 
conformational modifications as the origin of the observed 
aging effects in rat kidney m a l t a ~ e ~ ~  and in rat muscle 
GAPDH.27 None of these studies, however, provided direct, 
conclusive, evidence that there were no other changes in the 
old forms of these proteins and, hence, that purely conforma- 
tional alterations were indeed responsible for the effects seen. 
Direct evidence for the role of conformational changes in 
the age-related modifications in a protein was provided for 
the glycolytic enzyme phosphoglycerate kinase (PGK). This 
enzyme has been found to become modified in rat skeletal and 
cardiac muscle, as well as in brain and liver, during ag- 
ing.97-99 A s earch for covalent modifications detected 
none"' ; hence, experiments to test for noncovalent struc- 
tural changes were conducted. In these experiments, schemat- 
ically depicted in Figure 6, samples of both young and old 
PGK were unfolded extensively by guanidine:HCl to erase 
any differences in the folding pattern of the two proteins. 
When the denaturant was removed, allowing the proteins to 
refold and resume their biological activity, it was found that 
both became identical and behaved as young PGK.''','02 
This rejuvenation of old PGK by unfolding-refolding pro- 
vides conclusive evidence that the aging-related modifications 
"young" enzyme "old" enzyme 
natural 
P-= 
asins 
1111) 
denature protein I 
denaturant 
'I re-folded" enzyme 
'I unfolded It enzyme 
Figure 6. A schematic depiction of age-related structural modi- 
fications in a protein where the alterations are solely conforma- 
tional. The modified tertiary structure usually results in a defi- 
cient biological activity though the stability of the protein may 
actually increase. To test whether the age-related modifications 
are purely conformational, the old form of the protein can be 
extensively unfolded, using a strong denaturant, followed by 
refolding, which should regenerate the native young form of the 
protein. 
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affect only the conformation of this protein. Although the 
precise nature of the structural modifications in old PGK is 
still to be determined, experiments that simulated the aging 
process of this protein in vitro, producing an enzyme species 
identical to that found in old tissues, indicated that a tempo- 
rary oxidation of two cysteine residues to form a disulfide 
bridge serves as an intermediate step in the process. This 
model gained strong support from the observation that 
young PGK in which one of these cysteines has been co- 
valently blocked by methylation becomes resistant to in vitro 
aging.Io3 
Support for the hypothesis that structural modifications 
are more prevalent in old PGK because of its longer dwell 
time in the tissue relative to that in young animals, where its 
turnover rate is high, was provided by experiments in which 
endurance-trained rats were used.'04 Exercise-induced dam- 
age to muscle proteins triggers de novo protein synthesis and, 
hence, was expected to shorten the dwell time of proteins in 
these cells. Indeed, when PGK samples from young, sedentary 
old, and endurance-trained old rats were compared, the 
enzymes from the young and the trained old rats were found 
to be similar and very distinct from the old enzyme from 
sedentary old animals. Moreover, the old protein could be 
converted to its young counterpart by an unfolding-nfolding 
protocol as described above, Thus it appears quite likely that 
the age-related modifications observed in PGK are purely 
conformational, develop after the protein has folded to its 
native state, and are prevalent in old tissues because the rate 
of turnover of the protein is reduced (under sedentary condi- 
tions, but can be enhanced by exercise). It should, however, 
be emphasized that no direct proof of the longer dwell-time of 
PGK in old rat tissues has been provided and that other 
changes in the old cell (a reduction in the amount of protec- 
tion against conformational changes, for example) could 
possibly (though less likely) also explain the data. 
Amyloid Formation 
The native folded state of soluble, globular proteins, as a 
rule, places the hydrophobic amino acid residues in the inte- 
rior and brings only polar residues into contact with the 
aqueous solvent. Exposure of "sticky" domains rich in hy- 
drophobic amino acid residues leads to protein aggregation 
and precipitation, a common fate of misfolded proteins. The 
fact that age-modified PGK stays soluble and monomeric 
indicates that the structural alterations do not place such 
hydrophobic domains on the surface of this protein. In con- 
trast, a large number of age-associated diseases and patholo- 
gies are characterized by the deposition in tissues of aggre- 
gates composed of conformationally modified proteins. What 
is typical of these deposits, termed amyloid, is that they form 
fibrillar structures of variable length and with a diameter of 
60 to 100 A, in which the individual protein molecules 
assume a predominantly beta-sheet type secondary structure 
and assemble into a characteristic cross-beta repeat struc- 
ture.lo5 A model of the mechanism of formation of these 
structures is depicted schematically in Figure 7, though it is 
important to mention that this process is still not understood 
completely. In a recent review, Kelly lists 16 proteins with a 
high propensity to form amyloid and notes that they display 
little sequence or structural homology. ' 05  The similarity 
among amyloidogenic proteins is, thus, not in their native 
folded structure (they are, in fact, not amyloidogenic in their 
normal state) but rather in their tendency to undergo a 
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Figure 7. A schematic presentation of the conversion of a cor- 
rectly folded native protein into an amyloid deposit. The trans- 
formation involves the formation of a "sticky" intermediate 
characterized by a high content of beta-sheet secondary struc- 
ture, which has a propensity to organize into high molecular 
weight aggregates that form long, fibrillar structures. The high 
degree of molecular alignment in these fibrils causes them to 
display strong birefringence when stained by certain dyes (as 
Congo Red), which is one of the hallmarks of amyloid deposits. 
conformational modification and to acquire amyloidogenic- 
ity. A comparison of the evolution of amyloid deposits in 
different diseases indicates that the process does not follow a 
uniform pathway but rather is specific to the protein and the 
disease involved. Thus, in some cases, the amyloidogenic 
species may be an erroneously produced fragment of a pro- 
tein or a cleavage peptide that is part of the normal degrada- 
tion process of the protein, whereas in other cases, the amy- 
loid is formed from the intact protein in a "spontaneous" 
process, and in yet other cases, the aggregation of the other- 
wise normal protein is triggered by infection with the dis- 
eased form of the protein. Examples for proteins in the first 
category include fibrinogen fragments, whose deposition is 
responsible for hereditary renal amyloidosis,lo6 serum amy- 
loid A, whose fragment is involved in secondary systemic 
a m y l o i d o ~ i s , ' ~ ~  and the amyloid precursor protein whose 
cleavage product, beta-amyloid, forms amyloid deposits in 
the brain of Alzheimer's disease patients."* To the second 
category belong proteins such as the pancreatic hormone 
amylin, whose amyloid deposits are prevalent in non-insulin- 
dependent diabetes'09,' I" and transthyretin, which features 
in senile systemic amylo ido~is . '~~  The class of infectious 
amyloidogenic proteins includes the family of prion proteins 
that are deposited in the brain in a number of diseases 
including scrapie and Creutzfeldt-Jacob disease.1L'-'L3 
Many of the amyloidogenic diseases show a pronounced 
age-dependence in that their prevalence increases rapidly 
towards the end of the life span, reflecting the age-dependent 
propensity of the proteins involved to undergo the conforma- 
tional modifications. Possibly the best known of these dis- 
eases is Alzheimer's disease, which is characterized by the 
deposition of amyloid fibrils in the brain that are surrounded 
by dead or dying neurons.1o8 As mentioned earlier, these 
fibrils are composed mostly of the beta-amyloid peptide, a 
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40-43 amino acids fragment of the much larger amyloid 
precursor protein (APP). The conformational changes that 
convert the soluble peptide to its amyloidogenic form involve 
a transformation from a predominantly alpha-helical struc- 
ture, which is nonaggregatable, to a mostly beta-sheet struc- 
ture, which is highly aggregatable. These conformational 
transitions have been studied extensively and although they 
are, as yet, not fully understood, the contributions of specific 
electrostatic, as well as hydrophobic, interactions have been 
delineated, and important structural details have been de- 
rived by NMR, CD, and infrared spectr~scopies."~-"~ The 
beta-amyloid peptide has been shown to exist in normal brain 
tissue, but what causes the initiation of its deposition in some, 
but not all, persons is unknown. There is, however, com el 
ling evidence that these deposits are highly neurotoxic' I P -  
The deposition of amyloid composed of the 37 amino 
acids peptide amylin in the pancreas of patients with non- 
insulin-dependent diabetes mellitus (NIDDM) also involves 
the conversion of the peptide's secondary structure from a 
predominantly alpha helical one to a beta-sheet struc- 
ture.11y.'20 While this system has not been studied in as much 
detail as the beta-amyloid one, two amino acid residues in 
amylin, in positions 28, 29 in this peptide's sequence, were 
clearly implicated as key factors in the aggregation. This 
assignment is based on the comparison of the sequences of 
human amylin, which is highly amyloidogenic, with those of 
cat amylin, which is moderately amyloidogenic, and with rat 
amylin, which does not aggregate. The two serine residues 
occupying these positions in human amylin were found to 
determine the amyloidogenic propensity of this species.12' 
However, our understanding of the changes in the cellular 
environment responsible for amylin aggregation, as well as of 
the relevance of the amylin deposits in diabetes, is still 
sketchy. 
In some individuals, the thyroxine transporter plasma 
protein transthyretin (TTR) undergoes conformational mod- 
ifications that result in its aggregation and deposition as 
amyloid in the heart, leading to congestive heart failure. This 
condition, termed senile systemic amyloidosis, usually devel- 
ops around the age of 80 years and is thus clearly an aging- 
related disease. In its native state, TTR is a homotetrameric 
protein'22; however, under conditions that cause its dissoci- 
ation into monomeric subunits, the protein undergoes a 
conformational change and becomes highly amyloido- 
. Mutants of TTR isolated from individuals 
with the familial form of the disease (which is much more 
aggressive and displays an early onset) were found to form 
less stable protein tetramers and revealed a strong correlation 
between tetramer instability and amyloidogenicity as dis- 
cerned both from fibril formation in vitro and from the age of 
onset of the disease in vivo.'23 Based on these results, as well 
as on extensive biophysical studies, Kelly and coworkers have 
proposed a structure for the amyloidogenic intermediate of 
TTR in which the tertiary structure is modified but the 
secondary structure remains native. lo' As in the amyloido- 
genic diseases described above, the structural and mechanis- 
tic studies of fibril formation, while very instructive, do not 
provide a clear answer to the question of why the process is so 
strongly age related. Some possible reasons will be discussed 
below. 
Possible Reasons for the Age-Related Increase in Misfolded 
and Aggregated Proteins 
All age-related conformational modifications in proteins 
described in the previous section involve the conversion of a 
7.1 9,123,124 
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correctly folded protein into a conformational isomer. In 
some cases, this altered protein stays monomeric and soluble, 
albeit with modified properties (as the old forms of PGK and 
GAPDH); however, in many cases the new structure has a 
high propensity to self assemble into amyloid deposits. Sev- 
eral factors may account for the enhanced accumulation of 
the two types of conformationally modified proteins in old 
cells: 
1. The process of protein folding, as seen in any reaction, 
is driven toward the minimum in the free energy where the 
system reaches equilibrium and ceases to change. However, 
the biologically active (native) form of a protein may be 
associated with a structure which, though transiently stable, 
does not represent the equilibrium state, and, given enough 
time, the protein continues to fold to more stable conforma- 
tions. A striking example of this type of behavior is provided 
by plasminogen activator inhibitor-1 (PAI-1), a protein in- 
volved in the dismantling and removal of blood clots. The 
biologically active form of this protein is unstable and con- 
verts rapidly and spontaneously to a stable but inactive 
(latent) conformation. Although PAL1 may be an extreme 
case, many cellular proteins (including PGK and GAPDH) 
share this trait, and their longer dwell time in tissues of old 
animals allows this conversion to occur to a significantly 
higher level than in young tissues. In other cases, e.g., in 
prion-associated diseases, a similar conformational conver- 
sion may be triggered (catalyzed) by infection with the dis- 
eased form of the protein. 
2. As discussed in previous sections, there exists a large 
body of work demonstrating a progressive increase, with 
aging, in the level of proteins that have been covalently 
modified by reactions such as glycation and oxidation. The 
polypeptide chain, thus permanently altered, will, in princi- 
ple, encode a different folded structure for the protein, which 
in the majority of cases will be functionally deficient. This 
altered conformation may also expose “sticky” domains and 
thus promote aggregation. Such an increase with aging in the 
concentration of the amyloidogenic form of a protein may be 
responsible for the amyloid formation by the Alzheimer’s 
peptide12s.126 as well as by proteins involved in other amy- 
loidogenic diseases. 
3. While the information needed for the correct folding 
of a protein is believed to be contained in its amino acid 
sequence, it has become evident in recent years that the 
folding of most proteins in the cell does not occur indepen- 
dently but is assisted and catalyzed by auxiliary proteins. 
Some of these helper-proteins, such as protein disulfide 
isomerase and peptidyl prolyl isomerase, are enzymes that 
catalyze the formation of the correct disulfide bonds within 
proteins and the cis-trans isomerization of prolyl peptide 
bonds (two intrinsically slow reactions which, when not 
accelerated, tend to clog the folding pathway). Another im- 
portant group of folding-assistants are the molecular chaper- 
ones. These are proteins that help direct the folding along the 
correct pathway by inhibiting off-pathway processes and 
interactions. At the high concentration of proteins in the cell, 
these chaperone proteins play a crucial role as they reversibly 
bind to temporarily exposed “sticky” segments of the 
polypeptide chain (generated during folding or unfolding) 
and thus inhibit their aggregation,’277128 a process that would 
otherwise lead to the appearance of protein precipitates, 
called inclusion bodies, in the cell.’29 A pronounced induc- 
tion of chaperone protein production is a major organismal 
response to stressful conditions that damage cellular proteins, 
thereby triggering a burst of de novo protein synthesis and, 
hence, increasing the demand for chaperones. An age-related 
decline in the ability of cells to induce chaperone protein 
production in response to stress has been documented in a 
number of s t ~ d i e s ’ ~ ~ - ’ ” ~  and whereas the origins of this 
deficiency are still being sought, it appears likely that the 
structural fidelity of cellular proteins may be affected and that 
this deficiency can lead to the observed increase in the prev- 
alence of amyloidogenic diseases with aging. 
CONCLUSION 
More than 30 years have passed since Orgel proposed his 
Error Catastrophe theory in an attempt to provide a molec- 
ularly based explanation for aging. While later disproven, 
this hypothesis prompted the search for age-modified pro- 
teins that led, several years later, to the discovery of the first 
example of such species.26 We now know that many, though 
not all, proteins are modified in the tissues of old animals. 
More importantly, all the evidence thus far gathered indicates 
that these modifications are introduced by post-synthetic 
events and are not the result of deficiencies in the protein 
synthesizing machinery. A number of mechanisms that lead 
to protein modifications have been identified and studied, 
some introducing covalent alterations into the polypeptide 
chain with others affecting the fidelity of the folding pattern 
of the protein. The reduced ability of cells in old organisms to 
respond to stressful conditions by elevating the levels of 
chaperone proteins may feature in this age-related accumula- 
tion of misfolded proteins. Whereas the question of whether 
modified proteins are at  the forefront of the aging process or 
its victims has not been answered, it is clear that their accu- 
mulation in old tissues can be highly detrimental. Indeed, an 
increasing number of devastating diseases has been linked to 
the presence of structurally modified and functionally defec- 
tive proteins. Some of these diseases are strongly associated 
with aging and are characterized by the appearance of amy- 
loid deposits composed of misfolded, aggregated proteins in 
the diseased tissue. A search for the molecular basis of these 
diseases, and for successful intervention strategies, is cur- 
rently underway in a number of laboratories. This is a par- 
ticularly timely effort because with the projected increase in 
life expectancy, the number of people affected by diabetes, 
Alzheimer’s disease, etc., is expected to increase rapidly, and 
the importance of strategies to treat - or better yet, inhibit - 
these diseases cannot be overstated. 
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